Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems

Isabel Leroux-Roels; Marguerite Koutsoukos; Frédéric Clement; Sophia Steyaert; Michel Janssens; Patricia Bourguignon; Kristen Cohen; Marcus Altfeld; Pierre Vandepapelière; Louise Pedneault; Lisa McNally; Geert Leroux-Roels; Gerald Voss

doi:10.1016/j.vaccine.2010.08.035

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems

Vaccine. 2010 Oct 8;28(43):7016-24. doi: 10.1016/j.vaccine.2010.08.035. Epub 2010 Aug 20.

Authors

Isabel Leroux-Roels¹, Marguerite Koutsoukos, Frédéric Clement, Sophia Steyaert, Michel Janssens, Patricia Bourguignon, Kristen Cohen, Marcus Altfeld, Pierre Vandepapelière, Louise Pedneault, Lisa McNally, Geert Leroux-Roels, Gerald Voss

Affiliation

¹ Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium.

PMID: 20728522
DOI: 10.1016/j.vaccine.2010.08.035

Abstract

This randomized double-blind study aimed to determine the safety and immunogenicity of a gp120/NefTat candidate human immunodeficiency virus type 1 (HIV-1) vaccine formulated with one of three different Adjuvant Systems (AS02(A), AS02(V) and AS01(B)) in healthy HIV-seronegative adults. All vaccine formulations induced strong HIV-specific CD4(+) T-cell responses characterized by high lymphoproliferative capacity and IL-2 production that were still detectable 18 months after last immunization, with strongest responses seen in the AS01(B) group. Broad coverage was demonstrated against gp120, and to a lesser extent Nef, derived from the most common circulating clades (B, C and circulating recombinant form [CRF]-01). All vaccine formulations exhibited acceptable safety and reactogenicity profiles. The demonstration of superior CD4(+) T-cell induction by AS01(B) provides important guidance for future HIV vaccine development.

Publication types

Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

AIDS Vaccines / adverse effects
AIDS Vaccines / immunology*
Adjuvants, Immunologic / pharmacology
Adolescent
Adult
Antibodies, Neutralizing / blood
CD4-Positive T-Lymphocytes / immunology*
Cross Reactions
Double-Blind Method
Female
HIV Antibodies / blood
HIV Envelope Protein gp120 / immunology*
HIV Infections / immunology
HIV Infections / prevention & control*
HIV-1 / immunology
Humans
Immunity, Cellular
Interleukin-2 / immunology
Male
Middle Aged
Young Adult
nef Gene Products, Human Immunodeficiency Virus / immunology*
tat Gene Products, Human Immunodeficiency Virus / immunology*

Substances

AIDS Vaccines
Adjuvants, Immunologic
Antibodies, Neutralizing
HIV Antibodies
HIV Envelope Protein gp120
IL2 protein, human
Interleukin-2
gp120 protein, Human immunodeficiency virus 1
nef Gene Products, Human Immunodeficiency Virus
nef protein, Human immunodeficiency virus 1
tat Gene Products, Human Immunodeficiency Virus